A multi-arm clinical trial reports results of testing a strategy for the treatment of bladder cancer that uses standard immunotherapy plus biomarker assessment and targeted therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A novel risk score model based on five angiogenesis-related long non-coding RNAs for bladder urothelial carcinoma
Cancer Cell International Open Access 19 April 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Powles, T. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01317-6 (2021).
Powles, T. et al. JAMA Oncol. 3, e172411 (2017).
Loriot, Y. et al. N. Engl. J. Med. 381, 338–348 (2019).
Robinson, B. D. et al. Nat. Commun. 10, 1–11 (2019).
Siefker-Radtke, A. O. et al. J. Clin. Oncol. 37, 4511–4511 (2019).
de Bono, J. et al. N. Engl. J. Med. 382, 2091–2102 (2020).
Jette, N. R. et al. Cancers (Basel) 12, 687 (2020).
Milowsky, M. I. et al. BJU Int. 112, 462–470 (2013).
Iyer, G. et al. Science 338, 221 (2012).
Wan, X., Harkavy, B., Shen, N., Grohar, P. & Helman, L. J. Oncogene 26, 1932–1940 (2007).
Powles, T. et al. Eur. Urol. 69, 450–456 (2016).
Sargent, D. J., Conley, B. A., Allegra, C. & Collette, L. J. Clin. Oncol. 23, 2020–2027 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N. D. reports consulting for Vivreon Bioscience. S.K.P. reports consulting for Genentech, Aveo, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, BMS and Astellas.
Rights and permissions
About this article
Cite this article
Dizman, N., Meza, L. & Pal, S.K. Biomarker approach harnessed in trials of personalized medicine for bladder cancer. Nat Med 27, 761–763 (2021). https://doi.org/10.1038/s41591-021-01300-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01300-1
This article is cited by
-
A novel risk score model based on five angiogenesis-related long non-coding RNAs for bladder urothelial carcinoma
Cancer Cell International (2022)